Bent K Jakobsen
Overview
Explore the profile of Bent K Jakobsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
4602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff A, Chen Z, Bennett A, et al.
PLoS Pathog
. 2023 Dec;
19(12):e1011853.
PMID: 38100526
Engineered T cells hold great promise to become part of an effective HIV cure strategy, but it is currently unclear how best to redirect T cells to target HIV. To...
2.
Silk J, Abbott R, Adams K, Bennett A, Brett S, Cornforth T, et al.
J Immunol
. 2021 Dec;
208(1):169-180.
PMID: 34853077
Adoptive T cell therapy with T cells expressing affinity-enhanced TCRs has shown promising results in phase 1/2 clinical trials for solid and hematological tumors. However, depth and durability of responses...
3.
Holland C, Crean R, Pentier J, de Wet B, Lloyd A, Srikannathasan V, et al.
J Clin Invest
. 2020 Apr;
130(5):2673-2688.
PMID: 32310221
Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface-expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an anti-CD3 effector...
4.
Coles C, Mulvaney R, Malla S, Walker A, Smith K, Lloyd A, et al.
J Immunol
. 2020 Feb;
204(7):1943-1953.
PMID: 32102902
The molecular rules driving TCR cross-reactivity are poorly understood and, consequently, it is unclear the extent to which TCRs targeting the same Ag recognize the same off-target peptides. We determined...
5.
Lowe K, Cole D, Kenefeck R, OKelly I, Lepore M, Jakobsen B
Cancer Treat Rev
. 2019 Jun;
77:35-43.
PMID: 31207478
Immunotherapeutic strategies have revolutionised cancer therapy in recent years, bringing meaningful improvements in outcomes for patients with previously intractable conditions. These successes have, however, been largely limited to certain types...
6.
Madura F, Rizkallah P, Legut M, Holland C, Fuller A, Bulek A, et al.
Eur J Immunol
. 2019 May;
49(7):1052-1066.
PMID: 31091334
The HLA-A*02:01-restricted decapeptide EAAGIGILTV, derived from melanoma antigen recognized by T-cells-1 (MART-1) protein, represents one of the best-studied tumor associated T-cell epitopes, but clinical results targeting this peptide have been...
7.
Harper J, Adams K, Bossi G, Wright D, Stacey A, Bedke N, et al.
PLoS One
. 2018 Oct;
13(10):e0205491.
PMID: 30321203
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the...
8.
Lowe K, Mackall C, Norry E, Amado R, Jakobsen B, Binder G
Gene Ther
. 2018 May;
25(3):176-191.
PMID: 29789639
Adoptive T-cell therapy, incorporating engineered T cell receptors (TCRs) or chimeric antigen receptors (CARs), target tumor antigens with high affinity and specificity. To increase the potency of adoptively transferred T...
9.
Boudousquie C, Bossi G, Hurst J, Rygiel K, Jakobsen B, Hassan N
Immunology
. 2017 Jun;
152(3):425-438.
PMID: 28640942
The success of immune system-based cancer therapies depends on a broad immune response engaging a range of effector cells and mechanisms. Immune mobilizing monoclonal T cell receptors (TCRs) against cancer...
10.
Ojiro K, Qu X, Cho H, Park J, Vuidepot A, Lissin N, et al.
J Virol
. 2017 Mar;
91(10).
PMID: 28275182
The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been shown in an HCV replicon system but not in an authentic infectious HCV cell culture (HCVcc) system....